AI Article Synopsis

  • The study examined the effects of latanoprost therapy on lamina cribrosa (LC) thickness and depth in patients with primary open-angle glaucoma (POAG) and ocular hypertension (OHT) compared to healthy individuals.
  • Results showed that before therapy, LC thickness was significantly thinner in POAG/OHT patients.
  • After one and three months of latanoprost treatment, LC thickness increased while LC depth decreased, indicating positive changes in ocular health for treated patients.

Article Abstract

Purpose: To investigate that the changes of lamina cribrosa (LC) thickness and depth after latanoprost therapy in primary open-angle glaucoma (POAG) and ocular hypertension (OHT) patients.

Methods: In this single-center prospective cross-sectional study, 35 eyes from 35 patients with POAG or OHT (study group) and 26 age- and gender- matched healthy individuals (control group) were included. All participants were examined by spectral domain optical coherence tomography (SD-OCT) with enhanced depth imaging (EDI) mode for LC thickness and depth measurements at the first visit before latanoprost therapy and at visits after 1 (second visit) and 3 (third visit) months of latanoprost therapy.

Results: The mean LC thickness in both horizontal and vertical scans of the study group were thinner than the control group (p < 0.001, for both). During latanoprost therapy in the study group, the LC thickness values in horizontal scans significantly differed over the three visits, gradually increased (p < 0.05). There was significantly decrease in LC depth in horizontal scans between the first and third visits, and the second and third visits (p = 0.003 and p = 0.008, respectively). The gradual decrease in LC depth in vertical scans was observed at all visits, but the statistically significant difference was between the first and third visits only (p = 0.048).

Conclusion: POAG/OHT patients showed more LC thinning compared with healthy individuals. The significant increase in LC thickness and the significant decrease in LC depth were detected after IOP reduction therapy with latanoprost in ocular hypertensive/ glaucomatous eyes.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pdpdt.2024.104257DOI Listing

Publication Analysis

Top Keywords

latanoprost therapy
16
study group
12
decrease depth
12
third visits
12
lamina cribrosa
8
therapy primary
8
primary open-angle
8
open-angle glaucoma
8
ocular hypertension
8
thickness depth
8

Similar Publications

Glaucoma, a leading cause of blindness due to elevated intraocular pressure (IOP), is managed with medications like latanoprost (LAT), a prostaglandin analogue, to enhance aqueous outflow. Despite the challenge posed by eye anatomy and tear dynamics, effective ocular bioavailability via topical administration remains elusive. This study aims to optimize self-assembled nanomicelles incorporating LAT, an anti-glaucoma drug, belonging to BCS Class II (low solubility and high permeability) via a two-level, two-factor full factorial design, the nanomicelles were formulated via direct dissolution method and validated using design of expert.

View Article and Find Full Text PDF

A phase 3 adaptive dose selection trial of NCX 470, a nitric oxide-donating bimatoprost for open-angle glaucoma or ocular hypertension: The MONT BLANC study.

Contemp Clin Trials

December 2024

Author Employee of Nicox Ophthalmics, Nicox Ophthalmics, Inc. 4819 Emperor Blvd. Suite 400 Durham, NC 27703, United States.

Purpose: To identify the optimal dose of NCX 470, a nitric oxide (NO)-donating bimatoprost, for comparison to latanoprost in a phase 3 trial for open-angle glaucoma (OAG) or ocular hypertension (OHTN) using an adaptive dose selection design.

Patients And Methods: In this prospective, multicenter trial, subjects were randomized 1:1:1 to NCX 470 0.065 %, NCX 470 0.

View Article and Find Full Text PDF

Purpose: This prospective study aimed to assess the impact of topical latanoprost 0.005% treatment on the microvasculature of the macula and optic nerve head (ONH) in primary open-angle glaucoma (POAG).

Methods: Fifty-seven eyes of 31 subjects were enrolled.

View Article and Find Full Text PDF

Background: To evaluate and compare the long-term efficacy of medical treatments for normal tension glaucoma (NTG) in controlling intraocular pressure (IOP), and establish a hierarchical ranking based on their effectiveness. 'Long-term' is defined as a treatment duration of over 12 weeks in randomised controlled trials (RCTs).

Methods: This systematic review and model-based network meta-analysis (MBNMA) collected data of 795 patients with 997 eyes from RCTs.

View Article and Find Full Text PDF
Article Synopsis
  • LDPE bottles were selected as the container closure system for packaging Latanoprost ophthalmic solution, with an alternative manufacturer also providing similar bottles for evaluation.
  • An extractables and leachable (E&L) study along with a stability program assessed the quality of the solution in both sets of bottles, revealing an unknown impurity in one batch.
  • Further investigation identified the impurity as Epsilon-caprolactam, a leachable from the transportation packaging, highlighting the need to consider the entire supply chain in leachability assessments.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!